Compare TMC & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | COAG |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2020 | 2026 |
| Metric | TMC | COAG |
|---|---|---|
| Price | $2.45 | $34.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $10.90 | ★ $62.67 |
| AVG Volume (30 Days) | ★ 4.5M | 347.8K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.00 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $27.38 |
| 52 Week High | $10.05 | $55.42 |
| Indicator | TMC | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 23.68 | 50.57 |
| Support Level | N/A | $28.46 |
| Resistance Level | $4.81 | $38.87 |
| Average True Range (ATR) | 0.19 | 2.56 |
| MACD | -0.05 | 1.02 |
| Stochastic Oscillator | 4.18 | 76.54 |
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.